@article{ETD,
      recid = {7588},
      author = {Khoo, Vi V.},
      title = {Secondary analyses of dietary data from PRISM  clinical  trials to evaluate safety and efficacy of pegvaliase for  adults with PKU},
      publisher = {Oregon Health and Science University},
      school = {M.S.},
      address = {2019},
      number = {ETD},
      abstract = {Phenylketonuria (PKU) is a genetic disorder caused by a  deficiency of phenylalanine hydroxylase leading to  decreased conversion of phenylalanine (Phe) to tyrosine  (Tyr). Pegvaliase™ (Palynziq™, BioMarin Pharmaceutical  Inc., Novato, CA, USA), an injectable enzyme replacement  therapy decreases plasma Phe by converting Phe intro  trans-cinnamic acid and ammonia. This study aims to  evaluate the changes in the dietary composition of  participants with PKU on pegvaliase.},
      url = {http://digitalcollections.ohsu.edu/record/7588},
      doi = {https://doi.org/10.6083/9w0323552},
}